
BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Willan, Andrew Roger	POSITION TITLE Senior Scientist		
eRA COMMONS USER NAME NA	Professor of Biostatistics		
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i>)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
York University, Toronto ON	B.A.	1970	Economics/Mathematics
Queen's University, Kingston ON	B.Ed.	1972	Education
Queen's University, Kingston ON	M.Sc.	1976	Statistics
University of Western Ontario, London ON	Ph.D.	1979	Biostatistics

A. Positions and Honors.

Positions and Employment

1979-1980	Biostatistician, Cancer Agency, Vancouver BC
1980-1987	Head of Biometry, NCIC Clinical Trials Unit, Kingston ON
1987-1989	Associate Professor, Population Health, University of Guelph, Guelph ON
1989-1991	Head, Clinical Trials & Epidemiology, Sunnybrook Health Sciences Centre, Toronto ON
1991-2002	Professor, Clinical Epidemiology and Biostatistics, McMaster University, Hamilton ON
2002-present	Senior Scientist, CHES, SickKids Research Institute, Toronto ON
2002-present	Professor, Dalla Lana School of Public Health, University of Toronto, Toronto ON

Honors

1977-1979	NHRDP Graduate Fellowship
1995	Best Paper Award from the Society for Medical Decision Making, co-author
2000	Research Award for Methodology Excellence, ISPOR, primary author
2002	Research Award for Methodology Excellence, ISPOR, co-author
2003	Research Award for Methodology Excellence, ISPOR, co-author

B. Selected peer-reviewed publications (in chronological order).

(Publications selected from 190 peer-reviewed publications)

1. **Willan A**, Watts D. Meaningful multicollinearity measures. *Technometrics* 1978;**20**:407-412.
2. **Willan A**. Relative efficiency in survival analysis. *J Chron Dis* 1983; **36**:183-192.
3. Pater J, **Willan A**. Clinical trials as diagnostic tests. *Control Clin Trials* 1984; **5**:107-113.
4. Pater J, **Willan A**. Methodologic issues in trials of antiemetics. *J Clin Oncol* 1984; **2**:484-487.
5. **Willan A**, Pater J. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups. *J Chron Dis* 1985; **38**:603-608.
6. **Willan A**, Pater J. Carryover and the two-period crossover clinical trial. *Biometrics* 1986; **42**:593-599.
7. **Willan A**, Pater J. Using baseline measurements in the two period crossover clinical trial. *Control Clin Trials* 1986; **7**:282-289.

8. Burnett R, **Willan A**. Linear rank tests for randomized block designs. *Communications in Statistics A* 1988; **17**:2455-2470.
9. **Willan A**. Using the maximum test statistic in the two period crossover clinical trial. *Biometrics* 1988; **44**:211-218.
10. **Willan A**, MacKenzie T. The severity of illness and laboratory testing. *Can J Public Health* 1988; **79**:435-439.
11. **Willan A**, Ross W, MacKenzie T. A comparison of in-patient classification systems: A problem on non-nested regressions. *Stat Med* 1992; **11**:1321-1331.
12. **Willan A**. Power function arguments in support of an alternative approach for analyzing management trials. *Control Clin Trials* 1994; **15**:211-219.
13. **Willan A**, Cruess AF, Ballantyne M. Argon green vs krypton red laser photocoagulation of extrafoveal choroidal Neovascular Lesions: Three-year results in age-related macular generation. *Can J Ophthalmol* 1996; **31**:11-17.
14. **Willan A**, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's Theorem. *Health Economics* 1996; **5**:297-305. Addendum 1999; **8**(4).
15. Cook RJ, **Willan A**. Design considerations in crossover trials with a single interim analysis and serial patient entry. *Biometrics* 1996; **52**:732-739.
16. **Willan A**, O'Brien BJ, Cook DJ. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. *Control Clin Trials* 1997; **18**:121-130.
17. **Willan AR**, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. *Health Economics* 1999; **8**:203-211.
18. **Willan AR**, Lin DY. Incremental net benefit in randomized clinical trials. *Stat Med*. 2001; **20**:1563-1574. **PA**
19. **Willan AR**, Analysis, sample size and power for estimating incremental net health benefit from clinical trial data. *Control Clin Trials*. 2001; **22**:228-237.
20. **Willan AR**, O'Brien BJ. Cost prediction models for the comparison of two groups. *Health Economics* 2001; **10**:363-366.
21. **Willan AR**, O'Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. *Stat Med* 2001; **20**:3251-3259.
22. **Willan AR**. On the probability of cost-effectiveness using data from randomized clinical trials. *BMC Med Res Meth* 2001;1:8. (www.biomedcentral.com/1471-2288/1/8/)
23. Hoch JS, Briggs AH, **Willan AR**. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. *Health Economics* 2002; **11**:415-430.
24. **Willan AR**, Lin DY, Cook RJ, Chen E. Using inverse-weighting in cost-effectiveness analysis with censored data. *Statistical Methods in Medical Research* 2002; **11**:539-551.
25. **Willan AR**, Chen E, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with qualify-adjusted survival. *Statistics in Medicine* 2003; **22**:353-362.

26. **Willan AR.** Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. *European Journal of Gastroenterology and Hepatology* 2004; **16**:543-549.
27. **Willan AR,** Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. *Health Economics* 2004; **13**:461-475.
28. **Willan AR,** Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. *Statistics in Medicine* 2005; **24**:131-145.
29. **Willan AR,** Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. *Health Economics* 2005; **14**:327-328.
30. **Willan AR,** Pinto EM. The expected value of information and optimal clinical trial design. *Statistics in Medicine* 2005; **24**:1791-1806.
31. Pinto EM, **Willan AR,** O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. *Statistics in Medicine* 2005; **24**:1965-1982.
32. **Willan AR,** Goeree, R, Pinto EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in patients with parkinson's disease dementia. *Pharmacoeconomics* 2006; **24**: 93-106.
33. **Willan AR.** Statistical analysis of cost-effectiveness data from randomized clinical trials. *Expert Rev. Phamacoeconomics Outcomes Res.* 2006; **6**: 337-346.
34. Manca A, **Willan AR.** Lost in translation": accounting for between country differences in the analysis of multinational cost effectiveness data. *Pharmacoeconomics* 2006; **24**: 1101-1119.
35. Eckermann S, **Willan AR.** Expected value of information and decision making in HTA. *Health Economics* 2007; **16**: 195-209.
36. Pullenayegum EM, **Willan AR.** Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data. *Statistics in Medicine* 2007; **26**:3274-3299.
37. **Willan AR.** Clinical decision making and the expected value of information. *Clinical Trials* 2007; **4**(2):.
38. Hossain A, **Willan AR.** Approximate MLEs of the parameters of location-scale models under type II censoring. *Statistics* 2007; **41**(5): 385-394.
39. Boutis K, **Willan AR,** Babyn P, Narayanan UG, Alman B, Schuh S. A randomized, controlled trial of a removable brace versus casting in children with low-risk ankle fractures. *Pediatrics* 2007; **119**(6): e1256-e1263.
40. Eckermann S, **Willan AR.** Time and EVSI wait for no patient. *Value in Health* 2008; **11**: 522-526.
41. **Willan AR,** Kowgier ME. Cost-effectiveness Analysis of a Multinational RCT with a Binary Measure of Effectiveness and an Interacting Covariate. *Health Economics* 2008; **17**:777-791.
42. Eckermann S, **Willan AR.** The option value of delay in health technology assessment. *Medical Decision Making* 2008; **28**:300-305.
43. Eckermann S, Briggs A, **Willan AR.** Health technology assessment in the cost-disutility plane. *Medical Decision Making* 2008; **28**:172-181.

44. Eckermann S, **Willan AR**. Globally optimal trial design for local decision making. *Health Economics*, published online: Apr 24 2008. DOI: 10.1002/hec.1353.
45. **Willan AR**, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. *Clinical Trials* 2008; **5**: 289-300.
46. **Willan AR**. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials* 2008; **5**:587-594.
47. Murphy KE, Hannah ME, **Willan AR et al**. Multiple courses of antenatal corticosteroids for preterm birth study (MACS): a randomised controlled trial. *Lancet* 2008; **372**:2143-2151.

C. Research Support

Ongoing Research Support

1. Canadian Institutes of Health Research, SELAN (Structured Early Labour Assessment and care by Nurses) Trial. Hodnett ED (Principal Investigator), Stremler R, **Willan AR**, Fraser W, Gafni A, \$2,662,672, 2003-2007.
2. Canadian Institutes of Health Research, The Twin Birth Study. Barrett J (Principal Investigator), Hannah M, **Willan AR**, Ross S, Hutton E, *et al.*, \$8,608,045, 2003-2011.
3. National Science and Engineering Council, Development of Statistical Methodology in Cost-Effectiveness Analysis. **Willan AR** (Principal Investigator) \$55,000, 2003-2008.
4. Canadian Institutes of Health Research, Early External Cephalic Version 2 Trial. Hutton E (Principal Investigator) Hannah, M, **Willan AR**, Ross S, Gafni A, \$2,853,717.
5. Canadian Institutes of Health Research, A conceptual framework for outcome measurement in children: Consequences for health economic evaluation and decision- making. Ungar W (Principal Investigator), **Willan AR**, Marshall D, Feldman B, Wright J. \$225,000, 2003-2006.
6. University of Toronto, Dean's Fund. Goldman R (Principal Investigator), Mikrogianakis, **Willan A**, Koren G. Sublingual versus oral midazolam for laceration repair in the pediatric emergency department. \$10,000, 2003-2005.
7. Canadian Institutes of Health Research, Conventional versus liposomal amphotericin: an economic evaluation. Parshuram C, Upton A (Principal Investigators), Ungar W, Doyle J, **Willan AR**. \$50,828. 2004-2005.
8. Canadian Institutes of Health Research, Multiple Courses Of Antenatal Corticosteroids For Preterm Birth Study: 5 Year Follow-Up (MACS-5). Asztalos E (Principal Investigator), Hannah M, Ohlsson A, Ross S, Matthews S, Murphy K, **Willan AR**, Saigal S, Gafni A. \$3,585,161, 2005-2012.
9. Physician's Services Incorporated Foundation, Emergency Department Rapid Intravenous Rehydration for Pediatric Gastroenteritis: A Randomized Controlled Trial. Freedman S (Principal Investigator), Parkin P, Schuh S, **Willan AR**. \$156,000, 2006-2007.
10. Canadian Institutes of Health Research, Translating Research on Pain in Children (Team Grant). Stevens B (Principal Investigator), **Willan AR**, *et al.* \$5,928,858, 2006-2011.

11. Physician's Services Incorporated Foundation, Impact of Oximetry on Disposition in Acute Bronchiolitis. Schuh S (Principal Investigator), Freedman S, Coates A, Parkin P, Allen U, **Willan AR**, Ungar W, DaSilva Z. \$163,000 2008-2011.
12. Bloorview Research Institute, Functional Outcomes Following Orthopaedic Surgery Based On Gait Laboratory Versus Observational Gait Analysis In Ambulatory Children With Cerebral Palsy: A Pilot Randomized Controlled Trial. Narayana U (Principal Investigator), **Willan A**, *et al.* \$25,015, 2007-2008.
13. Canadian Institutes of Health Research, The Tips for Infant and Parental Sleep (TIPS) Trial. Stremler R (Principal Investigator), **Willan A**, *et al.* \$405,344, 2007-2009.
14. National Science and Engineering Council, Expected Value of Information and Optimal Trial Design. **Willan AR** (Principal Investigator) \$70,000, 2008-2013.